Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flow from operating activities:
Net loss	$ (28,288)	$ (21,459)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	812	242
Impairment loss on long-lived assets	0	114
Amortization of intangible assets	1,112	0
Accretion of debt discount	635	0
Change in fair value of contingent consideration	(268)	0
Stock-based compensation	1,343	(84)
Foreign currency transaction loss	0	676
Gain on debt extinguishment	(4,340)	(956)
Changes in operating assets and liabilities:
Accounts receivable	9,674	4,399
Inventory	122	0
Prepaid expenses and other current assets	2,600	2,137
Accounts payable	990	(45)
Accrued expenses	(1,110)	820
Deferred revenue	(1,939)	(2,174)
Research and development service obligation liabilities	(851)	93
Other long-term assets and liabilities	(266)	201
Net cash used in operating activities	(19,774)	(16,036)
Cash flow from investing activities:
Purchases of property and equipment	(3,209)	(4,515)
Landlord reimbursement of tenant improvement allowance	508	1,015
Payment for EPI Health Acquisition	(15,093)	0
Net cash used in investing activities	(17,794)	(3,500)
Cash flow from financing activities:
Proceeds from issuance of common stock and issuance and exercise of pre-funded warrants, net of underwriting fees and commissions	14,252	37,600
Proceeds from exercise of common stock warrants	0	461
Proceeds from issuance of common stock under common stock purchase agreement	0	6,334
Payment of note payable	(10,000)	0
Proceeds from common stock issued pursuant to equity distribution agreement (at-the-market facility)	1,334	0
Payments related to offering costs	(200)	(364)
Proceeds from exercise of stock options	0	58
Net cash provided by financing activities	5,386	44,089
Net (decrease) increase in cash, cash equivalents and restricted cash	(32,182)	24,553
Cash, cash equivalents and restricted cash as of beginning of period	47,668	35,879
Cash, cash equivalents and restricted cash as of end of period	15,486	60,432
Supplemental disclosure for cash flow information:
Interest paid	339	0
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment with accounts payable and accrued expenses	694	3,892
Right-of-use assets obtained in exchange for lease liabilities	0	1,343
Non-cash gain on debt extinguishment	4,340	956
Deferred offering costs reclassified to additional paid-in capital	0	364
Contingent consideration related to EPI Health Acquisition	3,648	0
Note payable issued for EPI Health Acquisition	13,305	0
Reconciliation to condensed consolidated balance sheets:
Cash and cash equivalents	14,903	59,960
Restricted cash included in noncurrent assets	583	472
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 15,486	$ 60,432